Unlocking Sulforaphane's Potential: Evgen's CEO Shares 2016 Plans
This article was originally published in Scrip
Sulforaphane, a potential anticancer agent and neuroprotectant found in brassica vegetables, is the basis of newly listed Evgen Pharma's technology, Sulforadex. Evgen has created a synthetic version of the molecule with its technology, which it believes will be successful in treating types of cancer, multiple sclerosis (MS) and subarachnoid hemorrhage. Scrip's Lubna Ahmed spoke to Evgen's CEO Dr. Stephen Franklin to find out more about where the company started, its technology and what we should expect from Evgen moving into 2016.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.